About US
Contact us
-
With 'Dear Scientist' campaign from BG BrandLab, Pfizer keeps researchers in the spotlightLetters from patients to scientists are at the heart of a new Pfizer-sponsored contentcampaignwith the Boston Globe’s BG BrandLab. The first installment of “Dear Scientist” debuted with a letter fr2017/10/18
-
AstraZeneca lobbies for personalized asthma care with new visual snapshot toolAstraZeneca wants asthma patients to know their treatment plans should be as unique and specific to them as a fingerprint. Its solution? Lungprint. A new interactive digital tool,Lungprintallows as2017/10/18
-
Padding its lung cancer lead, Merck's Keytruda helped PD-L1 patients live 30 months longerMerck’s immuno-oncology medication Keytruda has built up an imposing lead in lung cancer, and the company is touting more positive survival data to keep that lead intact. The New Jersey drugmaker u2017/10/17
-
Outcome Health launches internal probe, offers client audits after WSJ reportOutcome Health went into crisis communications mode after a Wall Street Journalarticlelast week said the fast-growing pharma services company had misled its advertisers. Within hours, the company post2017/10/17
-
Despite notable failures, cancer vaccines are poised for a leap onto the market: expertIt's no secret that cancer vaccines have turned in multiple late-stage failures, putting a serious damper on enthusiasm in the field. But one oncology expert believes we'll see licensed cancer vacci2017/10/16
-
GlaxoSmithKline wins first-ever nod for blockbuster vaccine prospect ShingrixJust as GlaxoSmithKline nears a decision from the U.S. FDA for its key shingles vaccine, Shingrix, Canada has become the first country to approve the shot—and it's a key piece of CEO Emma Walmsley's p2017/10/16
-
J&J prevails in first talc appeal as judges vacate $72M verdictJohnson & Johnson may have incidentally scored a major victory in the Supreme Court case brought by another drugmaker, Bristol-Myers Squibb. Because of a Bristol ruling this summer, J&J has2017/10/13
-
J&J's Remicade stands firm against biosim competition in Q3Under a growing biosimilar assault, Johnson & Johnson's big-selling immunology biologic Remicade held its ground again in the third quarter. Now, executives are planning their 2018 defense strat2017/10/13
-
Bisaro steers Impax to $6.4B Amneal merger, creating fifth-largest U.S. generics companySurprise, surprise: Impax Labs, looking tobulk upamid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal. On Tuesday, the companysaidit had inked an all2017/10/12
-
With Kite in the bag, Gilead boosts oncology chief Riva to the head tableWhat comes after a successful M&A hunt? A promotion for the lead deal scout. Weeks after sewing up a $11.9 billion deal for Kite Pharma and its cell therapy engine, Gilead Sciencessaidit's promoti2017/10/12